DARPA Highlights Singletto's Journey from Breakthrough Research to Real-World Deployment
The Defense Advanced Research Projects Agency (DARPA) has published a feature highlighting Singletto's journey from performer in DARPA's Personalized Protective Biosystems (PPB) program to participation in the Embedded Entrepreneur Initiative (EEI). The article chronicles the development of Oxafence® Active Protection technology and its transition from advanced research toward real-world military and healthcare applications.
The DARPA feature describes how Oxafence® has progressed from a novel active protection concept into evaluation and use within select military medical settings while continuing to expand toward broader commercial applications. It includes interviews with DARPA PPB Program Manager Dr. Eric Van Gieson and Singletto co-founder and CEO John Bjornson discussing the importance of successfully transitioning breakthrough technologies beyond the laboratory and into operational environments.
We are honored that DARPA selected Singletto as one of its commercialization success stories and grateful for the support of the DARPA team throughout our journey.